Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling.

Jha, NK; Arfin, S; Jha, SK; Kar, R; Dey, A; Gundamaraju, R; Ashraf, GM; Gupta, PK; Dhanasekaran, S; Abomughaid, MM; Das, SS; Singh, SK; Dua, K; Roychoudhury, S; Kumar, D; Ruokolainen, J; Ojha, S; Kesari, KK

Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling.

Jha, NK Arfin, S Jha, SK Kar, R Dey, A Gundamaraju, R Ashraf, GM Gupta, PK Dhanasekaran, S Abomughaid, MM Das, SS Singh, SK Dua, K

Roychoudhury, S Kumar, D Ruokolainen, J Ojha, S Kesari, KK

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Semin Cancer Biol, 2022
Issue Date:: 2022-02-23

Closed Access

	Filename	Description	Size
	YSCBI2207.pdf	Published version	8.55 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Jha, NK
dc.contributor.author	Arfin, S
dc.contributor.author	Jha, SK
dc.contributor.author	Kar, R
dc.contributor.author	Dey, A
dc.contributor.author	Gundamaraju, R
dc.contributor.author	Ashraf, GM
dc.contributor.author	Gupta, PK
dc.contributor.author	Dhanasekaran, S
dc.contributor.author	Abomughaid, MM
dc.contributor.author	Das, SS
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Roychoudhury, S
dc.contributor.author	Kumar, D
dc.contributor.author	Ruokolainen, J
dc.contributor.author	Ojha, S
dc.contributor.author	Kesari, KK
dc.date.accessioned	2022-03-09T04:03:56Z
dc.date.available	2022-02-20
dc.date.available	2022-03-09T04:03:56Z
dc.date.issued	2022-02-23
dc.identifier.citation	Semin Cancer Biol, 2022
dc.identifier.issn	1044-579X
dc.identifier.issn	1096-3650
dc.identifier.uri	http://hdl.handle.net/10453/155093
dc.description.abstract	Recent mounting evidence has revealed extensive genetic heterogeneity within tumors that drive phenotypic variation affecting key cancer pathways, making cancer treatment extremely challenging. Diverse cancer types display resistance to treatment and show patterns of relapse following therapy. Therefore, efforts are required to address tumor heterogeneity by developing a broad-spectrum therapeutic approach that combines targeted therapies. Inflammation has been progressively documented as a vital factor in tumor advancement and has consequences in epigenetic variations that support tumor instigation, encouraging all the tumorigenesis phases. Increased DNA damage, disrupted DNA repair mechanisms, cellular proliferation, apoptosis, angiogenesis, and its incursion are a few pro-cancerous outcomes of chronic inflammation. A clear understanding of the cellular and molecular signaling mechanisms of tumor-endorsing inflammation is necessary for further expansion of anti-cancer therapeutics targeting the crosstalk between tumor development and inflammatory processes. Multiple inflammatory signaling pathways, such as the NF-κB signaling pathway, JAK-STAT signaling pathway, MAPK signaling, PI3K/AKT/mTOR signaling, Wnt signaling cascade, and TGF-β/Smad signaling, have been found to regulate inflammation, which can be modulated using various factors such as small molecule inhibitors, phytochemicals, recombinant cytokines, and nanoparticles in conjugation to phytochemicals to treat cancer. Researchers have identified multiple targets to specifically alter inflammation in cancer therapy to restrict malignant progression and improve the efficacy of cancer therapy. siRNA-and shRNA-loaded nanoparticles have been observed to downregulate STAT3 signaling pathways and have been employed in studies to target tumor malignancies. This review highlights the pathways involved in the interaction between tumor advancement and inflammatory progression, along with the novel approaches of nanotechnology-based drug delivery systems currently used to target inflammatory signaling pathways to combat cancer.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Semin Cancer Biol
dc.relation.isbasedon	10.1016/j.semcancer.2022.02.022
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.title	Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-03-09T04:03:50Z
pubs.publication-status	Published online

Abstract:

Recent mounting evidence has revealed extensive genetic heterogeneity within tumors that drive phenotypic variation affecting key cancer pathways, making cancer treatment extremely challenging. Diverse cancer types display resistance to treatment and show patterns of relapse following therapy. Therefore, efforts are required to address tumor heterogeneity by developing a broad-spectrum therapeutic approach that combines targeted therapies. Inflammation has been progressively documented as a vital factor in tumor advancement and has consequences in epigenetic variations that support tumor instigation, encouraging all the tumorigenesis phases. Increased DNA damage, disrupted DNA repair mechanisms, cellular proliferation, apoptosis, angiogenesis, and its incursion are a few pro-cancerous outcomes of chronic inflammation. A clear understanding of the cellular and molecular signaling mechanisms of tumor-endorsing inflammation is necessary for further expansion of anti-cancer therapeutics targeting the crosstalk between tumor development and inflammatory processes. Multiple inflammatory signaling pathways, such as the NF-κB signaling pathway, JAK-STAT signaling pathway, MAPK signaling, PI3K/AKT/mTOR signaling, Wnt signaling cascade, and TGF-β/Smad signaling, have been found to regulate inflammation, which can be modulated using various factors such as small molecule inhibitors, phytochemicals, recombinant cytokines, and nanoparticles in conjugation to phytochemicals to treat cancer. Researchers have identified multiple targets to specifically alter inflammation in cancer therapy to restrict malignant progression and improve the efficacy of cancer therapy. siRNA-and shRNA-loaded nanoparticles have been observed to downregulate STAT3 signaling pathways and have been employed in studies to target tumor malignancies. This review highlights the pathways involved in the interaction between tumor advancement and inflammatory progression, along with the novel approaches of nanotechnology-based drug delivery systems currently used to target inflammatory signaling pathways to combat cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155093